Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors

Publication Date: September 28, 2023

Key Points

Key Points

  • The focus of this guideline is advanced or metastatic well-differentiated G1-G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including tumors arising in sites such as the pancreas, stomach, small intestine, colon, rectum, and appendix.
    • These are classified according to mitotic rate or Ki-67 index (a measure of the percentage of primary tumor cells that are dividing).
  • This guideline focuses on strategies for controlling the growth of these tumors.

Treatment

...reatme...

...commendations for G1–G3 GEP-NET...

...mendation 1.1Selection of initial treatment o...

...n 1.2All treatment decisions should be guid...

...ommendation 1.3Patients should be assessed f...


...Systemic Therapy for Metastatic G1–G2...

...t-line Systemic Therapy for G1–G2 GI-NETs...

Recommendation 2.1SSAs (octreotide or lanre...

...ion 2.2In the less common circumstance of...

...er-line Systemic Therapy for G1–G2 GI-NE...

...ommendation 2.3Peptide receptor radionuc...

...endation 2.4Everolimus is recommended f...


...ic Therapy for Metastatic G1–G2 Pa...

...st-line Systemic Therapy for G1–G2 pa...

...3.1SSAs (octreotide or lanreotide) are...

...ion 3.2Chemotherapy (e.g., capecitabine...

...mmendation 3.3Chemotherapy (e.g., CAPTEM), ev...

...nd- or Later-line Systemic Therapy for...

...dation 3.4PRRT for SSTR-positive tumors, chemo...


...Therapy for G3 GEP-NETs

...ndation 4.1The range of systemic options...


...WHO Classification and Grading Criteria for...


...mic Therapy for Tumor Control in Well-differ...


...hat cancer clinical trials are vital to inform m...